[
  {
    "ts": null,
    "headline": "Cencora Inc. stock outperforms competitors on strong trading day",
    "summary": "Cencora Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=275c9dc5b28ba32890f4a0b118919c3ab4be6aafa3c414c3a03bec897d1f2214",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754930880,
      "headline": "Cencora Inc. stock outperforms competitors on strong trading day",
      "id": 136338002,
      "image": "",
      "related": "COR",
      "source": "MarketWatch",
      "summary": "Cencora Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=275c9dc5b28ba32890f4a0b118919c3ab4be6aafa3c414c3a03bec897d1f2214"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons Growth Investors Will Love Cencora (COR)",
    "summary": "Cencora (COR) is well positioned to outperform the market, as it exhibits above-average growth in financials.",
    "url": "https://finnhub.io/api/news?id=1209309f32a888536acef32f27f99d17a560c3cc43c13988764379e8994dbe7b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754930703,
      "headline": "3 Reasons Growth Investors Will Love Cencora (COR)",
      "id": 136310841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "Cencora (COR) is well positioned to outperform the market, as it exhibits above-average growth in financials.",
      "url": "https://finnhub.io/api/news?id=1209309f32a888536acef32f27f99d17a560c3cc43c13988764379e8994dbe7b"
    }
  },
  {
    "ts": null,
    "headline": "Cardinal Health Q4 Preview: Accelerating Autoimmune, Urology, And Oncology, Buy",
    "summary": "Cardinal Health, Inc. is rated a Buy with a $239 fair value, driven by specialty growth in autoimmune, urology & oncology. Learn more on CAH stock here.",
    "url": "https://finnhub.io/api/news?id=6fc02075c813781cf3b3ffd19240d12044175cc77403f8c75a01b0c330e555a8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754919588,
      "headline": "Cardinal Health Q4 Preview: Accelerating Autoimmune, Urology, And Oncology, Buy",
      "id": 136301900,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1970763277/image_1970763277.jpg?io=getty-c-w1536",
      "related": "COR",
      "source": "SeekingAlpha",
      "summary": "Cardinal Health, Inc. is rated a Buy with a $239 fair value, driven by specialty growth in autoimmune, urology & oncology. Learn more on CAH stock here.",
      "url": "https://finnhub.io/api/news?id=6fc02075c813781cf3b3ffd19240d12044175cc77403f8c75a01b0c330e555a8"
    }
  }
]